AZ·Pfizer Vaccine 1st Dose Recipients Show 96% Antibody Response... 2nd Dose Recipients 99%

An official at the COVID-19 vaccination center is preparing Pfizer vaccines for citizens to receive. [Image source=Yonhap News]

[Asia Economy Reporter Hwang Sumi] A large-scale study on COVID-19 vaccines conducted in the UK found that approximately 96% of individuals who received the first dose of the AstraZeneca (AZ) or Pfizer vaccine developed antibodies that neutralize COVID-19. Furthermore, the antibody generation rate exceeded 99% in those who completed the second dose.

According to UK media on the 18th (local time), researchers from University College London (UCL) conducted an analysis study involving 8,517 vaccinated individuals in England and Wales. The researchers reported that 96.42% of people vaccinated with AstraZeneca (AZ) or Pfizer developed antibodies 28 to 34 days after the first dose, and 99.08% of recipients developed antibodies within 7 to 14 days after the second dose.

The researchers stated, "More than 9 out of 10 British adults vaccinated with AstraZeneca (AZ) or Pfizer developed antibodies within one month after the first dose," adding, "This study is the latest evidence showing that the UK's vaccination strategy is highly effective and represents a true scientific achievement during the pandemic."

This study was conducted by analyzing 13,232 antibody samples provided by 8,517 vaccinated adults. All participants had no antibodies before the first dose, and those with antibodies were excluded from the study. The average age of participants was 65, which the media reported was because the study included the initial population vaccinated in the UK starting from December 8 of last year.

According to the study, in the early stages of vaccination, antibodies developed faster in individuals who received the Pfizer vaccine compared to those who received the AstraZeneca (AZ) vaccine, but after four weeks, both groups showed almost identical antibody generation rates.

The researchers noted that the study paper, which includes early UK vaccine recipients, is currently undergoing peer review before being published in a medical journal.

This content was produced with the assistance of AI translation services.